This retrospective analysis of 139 patients with type 2 diabetes switched from prior anti-hyperglycemic therapy to basal-bolus insulin therapy with V-Go showed a significant and clinically relevant 1.52% reduction in A1C using a lower TDD of insulin after a mean of 5 months of therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.